Transcatheter Technologies GmbH, a Regensburg, Germany-based transcatheter heart valve company, closed €2.6m in Series B funding.
The round was led by Rolf Käse, PhD, (Tubaflex Beteiligungs GmbH) and chairman of the advisory board, with participation from existing investors and undisclosed new investors.
The company intends to use the capital to enter clinical trials later this year.
Incorporated in 2009 and led by Dr. Wolfgang Goetz, CEO, Hou-Sen Lim, CTO, Transcatheter Technologies is currently developing TRINITY, a proprietary system for transcatheter aortic valve implantation, which combines a novel anchoring mechanism with a delivery catheter to enable the valve prosthesis to be accurately and precisely positioned.
After full evaluation of valve prosthesis function, it can be repositioned without foreshortening of the valve prosthesis frame. The valve is pre-mounted on a detachable tip to simplify the assembly of the catheter system in the operating room.
03/05/2011: TRANSCATHETER TECHNOLOGIES Closes €1.7M Series A Financing